| HOME >> BIOLOGY >> TECHNOLOGY |
BRISBANE, Australia and SAN CLEMENTE, Calif., Oct. 2 /PRNewswire/ -- ImpediMed Ltd, a pioneer in the medical applications of bioimpedance technology and Metagenics, Inc., a global leader in science-based nutraceutical products, medical foods, and therapeutic lifestyle change programs, today announced an agreement to distribute ImpediMed technology in the United States and Canada. Metagenics' Australian affiliate, Health World, Ltd, has been a long-standing customer of the Brisbane-based medical device manufacturer.
"We've seen the synergies of combining ImpediMed's products for assessing fat and fluid status with our own research-based health and wellness products and programs, which we market to healthcare professionals," said Mike Katke, VP of Medical Marketing for San Clemente, California-based Metagenics. "Their scientifically-grounded approach and the reliability and portability of their technology made offering ImpediMed to our customers a simple decision."
ImpediMed CEO Greg Brown said, "Metagenics has been an outstanding Australian partner using ImpediMed's body composition analysis devices for several years. This expanded relationship makes sense in light of our mutual focus on addressing wellness and healthier life styles."
About Metagenics, Inc.
Metagenics, Inc. is a life sciences company and leading developer and
manufacturer of science-based nutraceuticals medical foods, and therapeutic
lifestyle change programs marketed to healthcare practitioners worldwide.
It is headquartered in San Clemente, Calif. with manufacturing and multiple
research facilities located in Gig Harbor, Wash., including its
MetaProteomics(R) Nutrigenomics Research Center and its Functional Medicine
Research Center(SM) for human clinical research. Metagenics holds multiple
proprietary formula patents and produces over 400 research-based products
to optimize health. The company demonstrates its commitment to purity and
quality through its certifica
'/>"/>
| SOURCE ImpediMed Ltd Copyright©2008 PR Newswire. All rights reserved |